

Oncology Today with Dr Neil Love: Immune Checkpoint Inhibitors in Urothelial Bladder Carcinoma (Interview Audio)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III JAVELIN Bladder 100 trial assessing the efficacy of maintenance avelumab and best supportive care (BSC) in patients with advanced bladder cancer who respond to front-line platinum-based chemotherapy demonstrated which outcome?**

  - A significant improvement in overall survival (OS) in comparison to BSC alone**
  - No improvement in OS in comparison to BSC alone
- 2. Which of the following adverse events are prevalent toxicities experienced by patients receiving avelumab?**

  - Hypertension and myocardial ischemia
  - Thrombocytopenia and neutropenia
  - Colitis and thyroid abnormalities**
- 3. Enfortumab vedotin, approved by the FDA for patients with previously treated advanced bladder cancer, belongs to which class of drugs?**

  - Antibody-drug conjugates**
  - Immune checkpoint inhibitors
  - Monoclonal antibodies
- 4. Results of the Phase III IMvigor130 trial evaluating atezolizumab or placebo, each with platinum-based chemotherapy, versus atezolizumab monotherapy for patients with previously untreated locally advanced or metastatic urothelial bladder carcinoma included which of the following outcomes?**

  - Statistically significant progression-free survival benefit with atezolizumab/chemotherapy compared to placebo/chemotherapy**
  - Statistically significant OS benefit with atezolizumab/chemotherapy compared to placebo/chemotherapy
  - Both a and b
  - Neither a nor b